DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology’s vitiligo forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of vitiligo over the forecast period?
Of all people diagnosed with vitiligo, how many cases are segmental or nonsegmental vitiligo?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least 10 years of forecast data for the following vitiligo subpopulations:
Sandeep Mahapatra, B.D.S., M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked with the state and central governments of India to plan, design, and conduct large-scale research and implementation projects on noncommunicable diseases, tobacco cessation, and childhood nutrition. He holds a master’s degree in public health with a specialization in epidemiology.
